Windward Bio gets $165M to take China-derived drug into Phase 3 asthma trial
A Swiss biotech with two experimental medicines from China, plus an in-house discovery team, has brought in $165 million to advance into late-stage testing. The startup, Windward Bio, has raised a ...
Luca Santarelli, Windward Bio CEO May 4, 2026 09:03 AM EDT FinancingStartupsChina Windward Bio gets $165M to take China-derived drug into Phase 3 asthma trial Kyle LaHucik Biotech Correspondent A Swiss biotech with two experimental medicines from China, plus an in-house discovery team, has brought in $165 million to advance into late-stage testing. The … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that